Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. More Details
Excellent balance sheet with limited growth.
Share Price & News
How has Cellectis's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ALCLS is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: ALCLS's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of French stocks.
7 Day Return
1 Year Return
Return vs Industry: ALCLS underperformed the French Biotechs industry which returned 35.2% over the past year.
Return vs Market: ALCLS underperformed the French Market which returned 48.5% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Cellectis's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StIf You Had Bought Cellectis (EPA:ALCLS) Stock A Year Ago, You Could Pocket A 93% Gain Today
2 months ago | Simply Wall StThese Analysts Think Cellectis S.A.'s (EPA:ALCLS) Sales Are Under Threat
3 months ago | Simply Wall StCellectis (EPA:ALCLS) Is In A Strong Position To Grow Its Business
Is Cellectis undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ALCLS's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ALCLS's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ALCLS is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.
PE vs Market: ALCLS is unprofitable, so we can't compare its PE Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALCLS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALCLS is good value based on its PB Ratio (2.6x) compared to the FR Biotechs industry average (4.3x).
How is Cellectis forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALCLS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ALCLS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ALCLS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ALCLS's revenue (36.9% per year) is forecast to grow faster than the French market (6.8% per year).
High Growth Revenue: ALCLS's revenue (36.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ALCLS is forecast to be unprofitable in 3 years.
How has Cellectis performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALCLS is currently unprofitable.
Growing Profit Margin: ALCLS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALCLS is unprofitable, and losses have increased over the past 5 years at a rate of 8% per year.
Accelerating Growth: Unable to compare ALCLS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALCLS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (21.8%).
Return on Equity
High ROE: ALCLS has a negative Return on Equity (-44.67%), as it is currently unprofitable.
How is Cellectis's financial position?
Financial Position Analysis
Short Term Liabilities: ALCLS's short term assets ($272.4M) exceed its short term liabilities ($46.9M).
Long Term Liabilities: ALCLS's short term assets ($272.4M) exceed its long term liabilities ($106.0M).
Debt to Equity History and Analysis
Debt Level: ALCLS's debt to equity ratio (8.5%) is considered satisfactory.
Reducing Debt: ALCLS's debt to equity ratio has increased from 0.7% to 8.5% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALCLS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ALCLS has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 37.6% each year.
What is Cellectis's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALCLS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALCLS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALCLS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALCLS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALCLS's dividend in 3 years as they are not forecast to pay a notable one for the French market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Andre Choulika (55 yo)
Dr. Andre Choulika, Ph.D. is the Founder of Cellectis SA and has been its Chief Executive Officer since 1999 and served as its Chairman since 2011 until November 5, 2020. Dr. Choulika is a pioneer in the a...
CEO Compensation Analysis
Compensation vs Market: Andre's total compensation ($USD1.15M) is above average for companies of similar size in the French market ($USD559.50K).
Compensation vs Earnings: Andre's compensation has increased whilst the company is unprofitable.
Experienced Management: ALCLS's management team is seasoned and experienced (5.3 years average tenure).
Experienced Board: ALCLS's board of directors are considered experienced (9.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.1%.
Cellectis S.A.'s company bio, employee growth, exchange listings and data sources
- Name: Cellectis S.A.
- Ticker: ALCLS
- Exchange: ENXTPA
- Founded: 1999
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €586.451m
- Shares outstanding: 45.46m
- Website: https://www.cellectis.com
Number of Employees
- Cellectis S.A.
- 8, rue de la Croix Jarry
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It op...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/16 19:39|
|End of Day Share Price||2021/05/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.